StemRIM

StemRIM EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of StemRIM (4599.T) as of Oct 15, 2026 is -33.83 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -26.20 % — a change of 29.10% (lower).

EBIT/Assets

-33.83 %

YoY

29.10%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of StemRIM is 2026 -33.83 % . Operating Income to Assets Ratio (EBIT/Assets) of StemRIM was 2025 -26.20 % . It decreases by 29.10% lower compared to the previous year.

The StemRIM EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-27.04 JPY
Jan 1, 2020
3.68 JPY
Jan 1, 2021
-5.43 JPY
Jan 1, 2022
-20.60 JPY
Jan 1, 2023
1.33 JPY
Jan 1, 2024
-22.84 JPY
Jan 1, 2025
-26.20 JPY
Jan 1, 2026
-33.83 JPY
The StemRIM EBIT/Assets history
YEAREBIT/AssetsYoY
-33.83 %+29.10%
-26.20 %+14.70%
-22.84 %-1,819.55%
1.33 %-106.45%
-20.60 %+279.24%
-5.43 %-247.55%
3.68 %-113.62%
-27.04 %+38.75%
-19.49 %+26.51%
-15.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemRIM Stock analysis

What does StemRIM do? StemRIM Inc is a biotechnology company based in Ibaraki-shi, Japan, operating within the Health Care sector. The company focuses on the research and development of regeneration-inducing medicines, specifically developing pharmaceuticals that promote functional regeneration and healing of damaged biological tissues without the use of living cells or tissues. StemRIM Inc went public via an IPO on August 9, 2019, and currently employs 44 full-time staff members. The company's primary product is a stem cell regeneration-inducing medicine, which aims to deliver therapeutic effects similar to regenerative medicine through oral administration alone, eliminating the need for live cell or tissue transplantation. StemRIM Inc maintains a website at stemrim.com, though specific details about its product development stage, clinical trials, or commercialization status are not provided in the available information. The company's headquarters are located in Ibaraki-shi, and it is listed on the Tokyo Stock Exchange under the ticker 4599.T with ISIN JP3399690001. No additional details about its founding year, key personnel, acquisitions, or financial figures are included in the provided data. StemRIM is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemRIM stock

Operating Income to Assets Ratio (EBIT/Assets) of StemRIM is -33.83 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of StemRIM changed from -26.20 % to -33.83 %, representing a 29.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) StemRIM since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s StemRIM with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — StemRIM

All Key Metrics — StemRIM